Innocoll AG (NASDAQ:INNL)‘s stock had its “buy” rating reissued by research analysts at JMP Securities in a note issued to investors on Sunday.
INNL has been the subject of several other research reports. Zacks Investment Research upgraded shares of Innocoll AG from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Tuesday, August 23rd. FBR & Co decreased their price objective on shares of Innocoll AG from $18.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 4th.
Shares of Innocoll AG (NASDAQ:INNL) traded up 13.48% during trading on Friday, hitting $3.03. The company had a trading volume of 12,554 shares. The stock’s 50-day moving average is $4.47 and its 200 day moving average is $6.04. The firm’s market capitalization is $89.99 billion. Innocoll AG has a 52-week low of $2.20 and a 52-week high of $12.94.
Innocoll AG (NASDAQ:INNL) last released its quarterly earnings data on Tuesday, November 22nd. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.03. Innocoll AG had a negative net margin of 1,284.37% and a negative return on equity of 40,867.96%. Equities research analysts predict that Innocoll AG will post ($2.34) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Innocoll AG stock. Rathbone Brothers increased its position in shares of Innocoll AG (NASDAQ:INNL) by 155.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 327,246 shares of the specialty pharmaceutical company’s stock after buying an additional 198,986 shares during the period. Rathbone Brothers’ holdings in Innocoll AG were worth $2,543,000 as of its most recent SEC filing. Institutional investors own 42.84% of the company’s stock.
Innocoll AG Company Profile